Harmony Biosciences (NASDAQ: HRMY)
Harmony Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Harmony Biosciences Company Info
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
News & Analysis
Why Harmony Biosciences Stock Got Slammed Today
The commercial-stage company was dinged by a bearish new take from a researcher.
Why Shares of Harmony Bioscience Are Falling on Friday
The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.
Why Shares of Harmony Bioscience Are Slumping Tuesday
A short-seller report drove the stock's shares down.
Investors Are Paying Attention to This Pharma That Is Gaining Speed
Can turning one product into a portfolio of products result in revenue magic?
Why Harmony Biosciences Stock Is Up 15% Today
The young biopharma outfit is set to become part of a major market index, which means a buying spree is on the radar.
Valuation
Earnings Transcripts
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2024.
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024.
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2024.
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.